SMStefania Marcenaro

Stefania Marcenaro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stefania Marcenaro has a total of 126 co-authors. Here are the top co-authors by number of shared publications:

  • Lorenzo Moretta

    Dipartimento dei Laboratori, Area di Ricerca di Immunologia, IRCCS Ospedale Bambino Gesù, Rome, Italy

    14 shared publications
  • Daniela Pende

    Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Universitaria San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

    11 shared publications
  • Alessandro Moretta

    Dipartimento di Medicina Sperimentale, Università degli Studi di Genova, Genoa, Italy

    10 shared publications
  • Maurizio Aricò

    Interdisciplinary Department of Medicine, Aldo Moro University of Bari, Bari, Italy

    9 shared publications
  • Paola Rivera

    From the Istituto Nazionale per la Ricerca sul Cancro, Genoa; Dipartimento di Medicina Sperimentale (DIMES), University of Genoa; Istituto Giannina Gaslini, Genoa; Center for Research, Transfer and High Education De novo therapies (DENOthe), University of Florence; Centro di Eccellenza per la Ricerca Biomedica, University of Genoa; and Dipartimento di Oncologia, Biologia e Genetica (DOBIG), University of Genoa, Italy

    8 shared publications
  • Cristina Bottino

    Department of Experimental Medicine (DIMES), University of Genoa, 16132 Genoa, Italy

    7 shared publications

Latest Publications

  • 2B4 dysfunction in XLP1 NK cells: More than inability to control EBV infection

    by Daniela Pende, Raffaella Meazza, Stefania Marcenaro, Maurizio Aricò, Cristina Bottino


  • Inhibitory 2B4 contributes to NK cell education and immunological derangements in XLP1 patients

    by Raffaella Meazza, Michela Falco, Stefania Marcenaro, Fabrizio Loiacono, Paolo Canevali, Francesca Bellora, Claudia Tuberosa, Franco Locatelli, Concetta Micalizzi, Alessandro Moretta, et al.

    X‐linked lymphoproliferative disease 1 (XLP1) is an inherited immunodeficiency, caused by mutations in SH2D1A encoding Signaling Lymphocyte Activation Molecule (SLAM)‐associated protein (SAP). In XLP1, 2B4, upon engagement with CD48, has inhibitory instead of activating function. This causes a selective inability of cytotoxic effectors to kill EBV‐infected cells, with dramatic clinical sequelae. Here, we investigated the NK cell education in XLP1, upon characterization of killer Ig‐like receptor (KIR)/KIR‐L genotype and phenotypic repertoire of self‐HLA class I specific inhibitory NK receptors (self‐iNKRs). We also analyzed NK‐cell cytotoxicity against CD48+ or CD48− KIR‐ligand matched or autologous hematopoietic cells in XLP1 patients and healthy controls. XLP1 NK cells may show a defective phenotypic repertoire with substantial proportion of cells lacking self‐iNKR. These NK cells are cytotoxic and the inhibitory 2B4/CD48 pathway plays a major role to prevent killing of CD48+ EBV‐transformed B cells and M1 macrophages. Importantly, self‐iNKR defective NK cells kill CD48− targets, such as mature DCs. Self‐iNKR− NK cells in XLP1 patients are functional even in resting conditions, suggesting a role of the inhibitory 2B4/CD48 pathway in the education process during NK‐cell maturation. Killing of autologous mature DC by self‐iNKR defective XLP1 NK cells may impair adaptive responses, further exacerbating the patients’ immune defect.


  • Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis

    by Raffaella Meazza, Claudia Tuberosa, Valentina Cetica, Michela Falco, Silvia Parolini, Sam Grieve, Gillian M. Griffiths, Elena Sieni, Stefania Marcenaro, Concetta Micalizzi, et al.


  • Open Access

    Variations of the UNC13D Gene in Patients with Autoimmune Lymphoproliferative Syndrome

    by Maurizio Aricò, Elena Boggio, Valentina Cetica, Matteo Melensi, Elisabetta Orilieri, Nausicaa Clemente, Giuseppe Cappellano, Sara Buttini, Maria Felicia Soluri, Cristoforo Comi, et al.

    Autoimmune lymphoproliferative syndrome (ALPS) is caused by genetic defects decreasing Fas function and is characterized by lymphadenopathy/splenomegaly and expansion of CD4/CD8 double-negative T cells. This latter expansion is absent in the ALPS variant named Dianzani Autoimmune/lymphoproliferative Disease (DALD). In addition to the causative mutations, the genetic background influences ALPS and DALD development. We previously suggested a disease-modifying role for the perforin gene involved in familial hemophagocytic lymphohistiocytosis (FHL). The UNC13D gene codes for Munc13-4, which is involved in perforin secretion and FHL development, and thus, another candidate for a disease-modifying role in ALPS and DALD. In this work, we sequenced UNC13D in 21 ALPS and 20 DALD patients and compared these results with sequences obtained from 61 healthy subjects and 38 multiple sclerosis (MS) patients. We detected four rare missense variations in three heterozygous ALPS patients carrying p.Cys112Ser, p.Val781Ile, and a haplotype comprising both p.Ile848Leu and p.Ala995Pro. Transfection of the mutant cDNAs into HMC-1 cells showed that they decreased granule exocytosis, compared to the wild-type construct. An additional rare missense variation, p.Pro271Ser, was detected in a healthy subject, but this variation did not decrease Munc13-4 function. These data suggest that rare loss-of-function variations of UND13D are risk factors for ALPS development.


  • A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes

    by Yenan T. Bryceson, Daniela Pende, Andrea Maul-Pavicic, Kimberly C. Gilmour, Heike Ufheil, Thomas Vraetz, Samuel C. Chiang, Stefania Marcenaro, Raffaella Meazza, Ilka Bondzio, et al.

    Familial hemophagocytic lymphohistiocytosis (FHL) is a life-threatening disorder of immune regulation caused by defects in lymphocyte cytotoxicity. Rapid differentiation of primary, genetic forms from secondary forms of hemophagocytic lymphohistiocytosis (HLH) is crucial for treatment decisions. We prospectively evaluated the performance of degranulation assays based on surface up-regulation of CD107a on natural killer (NK) cells and cytotoxic T lymphocytes in a cohort of 494 patients referred for evaluation for suspected HLH. Seventy-five of 77 patients (97%) with FHL3-5 and 11 of 13 patients (85%) with Griscelli syndrome type 2 or Chediak-Higashi syndrome had abnormal resting NK-cell degranulation. In contrast, NK-cell degranulation was normal in 14 of 16 patients (88%) with X-linked lymphoproliferative disease and in 8 of 14 patients (57%) with FHL2, who were identified by diminished intracellular SLAM-associated protein (SAP), X-linked inhibitor of apoptosis protein (XIAP), and perforin expression, respectively. Among 66 patients with a clinical diagnosis of secondary HLH, 13 of 59 (22%) had abnormal resting NK-cell degranulation, whereas 0 of 43 had abnormal degranulation using IL-2–activated NK cells. Active disease or immunosuppressive therapy did not impair the assay performance. Overall, resting NK-cell degranulation below 5% provided a 96% sensitivity for a genetic degranulation disorder and a specificity of 88%. Therefore, degranulation assays allow a rapid and reliable classification of patients, benefiting treatment decisions.


  • STXBP2 mutations in children with familial haemophagocytic lymphohistiocytosis type 5

    by Valentina Cetica, Alessandra Santoro, Kimberly C Gilmour, Elena Sieni, Karin Beutel, Daniela Pende, Stefania Marcenaro, Florian Koch, Samantha Grieve, Rachel Wheeler, et al.

    Background: Familial haemophagocytic lymphohistiocytosis (FHL) is a rare immune deficiency with uncontrolled inflammation; the clinical course usually starts within the first years of life, and is usually fatal unless promptly treated and then cured with haematopoietic stem cell transplant. FHL is caused by genetic mutations resulting in defective cell cytotoxicity; three disease related genes have been identified to date: perforin, Munc13-4 and syntaxin-11. A fourth gene, STXBP2, has been identified very recently as responsible for a defect in Munc18-2 in FHL-5. Aims: To describe the result of the screening of families with HLH and previously unassigned genetic defects. Methods: Patients with HLH diagnosed according to current diagnostic criteria, and who lacked mutations in the PRF1, Munc13-4, and STX11 genes were sequenced for mutations in STXBP2. Functional study was performed when material was available. Results: Among the 28 families investigated, 4 (14%) with biallelic STXBP2 mutations were identified. They originated from Italy, England, Kuwait and Pakistan. The p.Pro477Leu resulting from c.1430C>T, and p.Arg405Gln resulting from the single c.1214G>A nucleotide change are known, while we contribute two novel mutations: p.Glu132Ala resulting from c.395A>C, and p.Gly541Ser, resulting from c.1621G>A. The detrimental effect of the p.Gly541Ser mutation was documented biochemically and functionally in NK and CD8 cells. Additional polymorphisms are also described. Conclusion: These data expand current knowledge on the genetic heterogeneity of FHL and suggest that patients with FHL5 may have different results in degranulation assays under different conditions.


  • Combined Genotypic and Phenotypic Killer Cell Ig-Like Receptor Analyses Reveal KIR2DL3 Alleles Displaying Unexpected Monoclonal Antibody Reactivity: Identification of the Amino Acid Residues Critical for Staining

    by Michela Falco, Elisa Romeo, Stefania Marcenaro, Massimo Vitale, Cristina Bottino, Maria Cristina Mingari, Lorenzo Moretta, Alessandro Moretta, Daniela Pende

    In humans, recent clinical and experimental data from hematopoietic stem cell transplantation revealed that donor-derived alloreactive NK cells exert a beneficial graft versus leukemia effect. The existence of donor-derived alloreactive NK cells can be predicted on the basis of donor killer cell Ig-like receptor (KIR) gene profile and HLA class I typing of both donor and recipient. Moreover, the size of the alloreactive NK cell population can be directly assessed by the combined use of anti–KIR-specific mAb. In this study, in an attempt to improve the definition of alloreactive NK cell subsets, we assessed the KIR genotype and phenotype in a cohort of 44 donors. This approach allowed the identification of two different KIR2DL3 alleles (KIR2DL3*005 and the novel allele KIR2DL3*015) that did not react with the anti–KIR2DL3-specific ECM41 mAb. In contrast, both alleles were recognized at the cell surface by several mAb reacting with KIR2DL2/L3/S2. Notably, KIR2DL3*005 was also stained by the anti–KIR2DL1/S1-specific EB6B and 11PB6 mAb. Functional analysis revealed that, despite its particular mAb reactivity, the specificity of KIR2DL3*005 for HLA-C molecules did not differ from that of other KIR2DL2/L3 alleles. Finally, site-directed mutagenesis demonstrated that glutamine at position 35 is required for ECM41 staining, whereas glutamic acid 35 and arginine 50 are relevant for staining with EB6B or 11PB6 mAb. Our present data represent a substantial progress in the characterization of the NK cell repertoire and an improved phenotypic/functional definition of given KIR+ subsets.


  • OR.69. Alloreactive NK Cells Exert Anti-leukemia Activity in Haplo-HSCT to Pediatric Patients: Revised Role of Activating and Inhibitory KIR

    by Stefania Marcenaro, Stefania Martini, Michela Falco, Maria Ester Bernardo, Franco Locatelli, Alessandro Moretta, Lorenzo Moretta, Daniela Pende

  • Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity

    by Daniela Pende, Stefania Marcenaro, Michela Falco, Stefania Martini, Maria Ester Bernardo, Daniela Montagna, Elisa Romeo, Céline Cognet, Miryam Martinetti, Rita Maccario, et al.

    We analyzed 21 children with leukemia receiving haploidentical hematopoietic stem cell transplantation (haplo-HSCT) from killer immunoglobulin (Ig)–like receptors (KIR) ligand-mismatched donors. We showed that, in most transplantation patients, variable proportions of donor-derived alloreactive natural killer (NK) cells displaying anti-leukemia activity were generated and maintained even late after transplantation. This was assessed through analysis of donor KIR genotype, as well as through phenotypic and functional analyses of NK cells, both at the polyclonal and clonal level. Donor-derived KIR2DL1+ NK cells isolated from the recipient displayed the expected capability of selectively killing C1/C1 target cells, including patient leukemia blasts. Differently, KIR2DL2/3+ NK cells displayed poor alloreactivity against leukemia cells carrying human leukocyte antigen (HLA) alleles belonging to C2 group. Unexpectedly, this was due to recognition of C2 by KIR2DL2/3, as revealed by receptor blocking experiments and by binding assays of soluble KIR to HLA-C transfectants. Remarkably, however, C2/C2 leukemia blasts were killed by KIR2DL2/3+ (or by NKG2A+) NK cells that coexpressed KIR2DS1. This could be explained by the ability of KIR2DS1 to directly recognize C2 on leukemia cells. A role of the KIR2DS2 activating receptor in leukemia cell lysis could not be demonstrated. Altogether, these results may have important clinical implications for the selection of optimal donors for haplo-HSCT.


  • Defective CD107a Surface Expression Heralds Munc13-4 Defect and Discriminates Between Genetic Subtypes of Familial Hemophagocytic Lymphohistiocytosis (FHL)

    by Daniela Pende, Stefania Marcenaro, Stefania Martini, Alessandra Santoro, Gillian Griffiths, Maurizio Aricò, Lorenzo Moretta